<SEC-DOCUMENT>0001493152-25-003376.txt : 20250123
<SEC-HEADER>0001493152-25-003376.hdr.sgml : 20250123
<ACCEPTANCE-DATETIME>20250123154558
ACCESSION NUMBER:		0001493152-25-003376
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250123

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Phio Pharmaceuticals Corp.
		CENTRAL INDEX KEY:			0001533040
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-86901
		FILM NUMBER:		25549913

	BUSINESS ADDRESS:	
		STREET 1:		11 APEX DRIVE, SUITE 300A
		STREET 2:		PMB 2006
		CITY:			MARLBOROUGH
		STATE:			MA
		ZIP:			01752
		BUSINESS PHONE:		(508) 767-3861

	MAIL ADDRESS:	
		STREET 1:		11 APEX DRIVE, SUITE 300A
		STREET 2:		PMB 2006
		CITY:			MARLBOROUGH
		STATE:			MA
		ZIP:			01752

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RXi Pharmaceuticals Corp
		DATE OF NAME CHANGE:	20111019

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Orca Capital AG
		CENTRAL INDEX KEY:			0002052389
		ORGANIZATION NAME:           	
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			2M
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G

	BUSINESS ADDRESS:	
		STREET 1:		SPERLRING 2
		CITY:			PFAFFENHOFEN
		STATE:			2M
		ZIP:			85276
		BUSINESS PHONE:		498441 78644 14

	MAIL ADDRESS:	
		STREET 1:		SPERLRING 2
		CITY:			PFAFFENHOFEN
		STATE:			2M
		ZIP:			85276
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: Orca Capital AG -->
          <cik>0002052389</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>


    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <securitiesClassTitle>Common Stock, par value $0.0001 per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>12/19/2024</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001533040</issuerCik>
        <issuerName>Phio Pharmaceuticals Corp.</issuerName>
        <issuerCusip>71880W501</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>11 Apex Drive,</com:street1>
          <com:street2>Suite 300A, PMB 2006</com:street2>
          <com:city>Marlborough</com:city>
          <com:stateOrCountry>MA</com:stateOrCountry>
          <com:zipCode>01752</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Orca Capital AG</reportingPersonName>
      <citizenshipOrOrganization>2M</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>514965.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>514965.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>514965.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>9.9</classPercent>
      <typeOfReportingPerson>CO</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Phio Pharmaceuticals Corp.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>11 Apex Drive, Suite 300A, PMB 2006 Marlborough, Massachusetts 01752</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>Orca Capital AG</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>Sperlring 2 85276 Hettenshausen Deutschland</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Germany</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>514,965

From December 19, 2024 to the date of this Schedule, the Reporting Person acquired the Issuer's Common Stock in the following amounts: 109,298 shares, 60,000 shares, 350 shares, 332,668 shares, 244,445 shares, and 152,500 shares. During the same period, the Reporting Person disposed of the Issuer's Common Stock in the following amounts: 29,316 shares, 9,825 shares, 130,157 shares, 350 shares, 332,668 shares, 151,597 shares, 200 shares, 92,848 shares, 8,800 shares, and 6,500 shares.

The foregoing excludes shares of Common Stock issuable upon the exercise of certain warrants containing blocker provisions. The Reporting Person does not have the right to exercise warrants for 474,298 shares of Common Stock and 776,261 shares of Common Stock to the extent that such exercises would result in beneficial ownership of the Issuer's Common Stock by the Reporting Person of more than 4.9% or 9.9%, respectively.</amountBeneficiallyOwned>
        <classPercent>9.9</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>514,965</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>0</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>514,965</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>0</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>Orca Capital AG</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Thomas Konig</signature>
        <title>Thomas Konig/Director</title>
        <date>01/23/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
